This company has been marked as potentially delisted and may not be actively trading. NASDAQ:XTLB XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock About XTL Biopharmaceuticals Stock (NASDAQ:XTLB) 30 days 90 days 365 days Advanced Chart Get XTL Biopharmaceuticals alerts:Sign Up Key Stats Today's Range$1.13▼$1.1350-Day Range$3.43▼$5.2052-Week Range$0.86▼$3.05VolumeN/AAverage Volume9,993 shsMarket Capitalization$6.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. Read More XTL Biopharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreXTLB MarketRank™: XTL Biopharmaceuticals scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for XTL Biopharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioXTL Biopharmaceuticals has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.34% of the float of XTL Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXTL Biopharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XTL Biopharmaceuticals has recently decreased by 47.01%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXTL Biopharmaceuticals does not currently pay a dividend.Dividend GrowthXTL Biopharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.34% of the float of XTL Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXTL Biopharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XTL Biopharmaceuticals has recently decreased by 47.01%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for XTL Biopharmaceuticals this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XTL Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders29.00% of the stock of XTL Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.40% of the stock of XTL Biopharmaceuticals is held by institutions.Read more about XTL Biopharmaceuticals' insider trading history. Receive XTLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XTLB Stock News HeadlinesXTL Biopharmaceuticals Approves Key Resolutions at Shareholder MeetingJuly 28, 2025 | tipranks.comXTL Biopharmaceuticals Stock (NASDAQ:XTLB), Insider Trading ActivityJuly 8, 2025 | benzinga.comBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.August 30 at 2:00 AM | Altimetry (Ad)XTL Biopharmaceuticals Ltd. (XTLB) - Yahoo FinanceJune 30, 2025 | uk.finance.yahoo.comXTL Biopharmaceuticals names Noam Band as CEOApril 9, 2025 | uk.investing.comXTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive OfficerApril 8, 2025 | finanznachrichten.deXTL Biopharmaceuticals Appoints Noam Band as CEOApril 7, 2025 | tipranks.comXTL Names Mr. Noam Band as its New Chief Executive OfficerApril 7, 2025 | globenewswire.comSee More Headlines XTLB Stock Analysis - Frequently Asked Questions How were XTL Biopharmaceuticals' earnings last quarter? XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) announced its quarterly earnings data on Monday, December, 30th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter. When did XTL Biopharmaceuticals' stock split? Shares of XTL Biopharmaceuticals reverse split on Friday, February 10th 2017.The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of XTL Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that XTL Biopharmaceuticals investors own include Regulus Therapeutics (RGLS), Akari Therapeutics (AKTX), Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), Supernus Pharmaceuticals (SUPN) and Titan Pharmaceuticals (TTNP). Company Calendar Last Earnings12/30/2024Today8/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED-DRUGS Sub-IndustryN/A Current SymbolNASDAQ:XTLB CIK1023549 Webwww.xtlbio.com Phone(729) 955-7080Fax972-3611-6605EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.61 Sales & Book Value Annual Sales$450 thousand Price / Sales14.90 Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book1.23Miscellaneous Outstanding Shares5,450,000Free Float3,869,000Market Cap$6.70 million OptionableNot Optionable Beta1.09 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:XTLB) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
